KOSDAQElectronic Components228850

Rayence

₩7,160▼ 0.97%2026-11-18 close
Market Cap
₩115.1B
Turnover
₩100M
Volume
10K
Shares out.
16.1M
PER
408.3×
PBR
0.5×
EPS
₩18
Dividend Yield
4.08%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩300 per share · Prices as of the 2026-11-18 close

01

Report overview

Industrial demand sustains profit; net income still lags

Industrial CMOS detector demand kept operating profit positive from Q1 through Q3 2026, but a non-operating loss pushed attributable net income into a Q3 loss, leaving net profit and the revenue trend as the next items to confirm.

  1. 1

    After an operating loss of KRW 3.95 billion in 2025, operating profit posted KRW 3.58 billion in Q1 2026, KRW 2.51 billion in Q2 and KRW 3.51 billion in Q3.

  2. 2

    Sales to the semiconductor AXI inspection market reached KRW 18.87 billion in cumulative Q3 2026, above the KRW 13 billion recorded for full-year 2025, according to the company's preliminary release of November 11, 2026.

  3. 3

    The Q3 2026 attributable net loss of KRW 1.42 billion ran against operating profit, and press calculations put the quarter's non-operating loss at about KRW 5.4 billion.

  4. 4

    Revenue peaked at KRW 36.8 billion in Q1 2026 and then declined for two straight quarters to KRW 36.5 billion and KRW 35.9 billion, although Q3 revenue still rose 22.2% from a year earlier.

  5. 5

    Attributable net income for the last four quarters, from Q4 2025 to Q3 2026, totals KRW 300 million, a far smaller figure than the operating profit trend over the same period.

02

Business structure

Rayence develops and manufactures digital X-ray detectors based on TFT (thin-film transistor) and CMOS (complementary metal-oxide-semiconductor) technologies. It was spun off from a dental imaging maker in 2011 and supplies intraoral sensors and detectors to industrial, medical, dental and veterinary markets.

The company says it is the only domestic maker producing both TFT and CMOS detectors, and press reports describe its intraoral dental sensors as holding the top share of the global market. Its segments are dental, industrial and veterinary.

In the Q3 2026 preliminary release of November 11, 2026, dental sales were KRW 13.28 billion, up 38.5% year over year, industrial detector sales were KRW 5.11 billion, up 43.3%, and veterinary imaging sales were KRW 10.96 billion, up 21.3%.

CMOS detector sales rose 55.8% to KRW 11.3 billion, and intraoral sensor sales rose 19.9% to KRW 7.85 billion. Sales to the semiconductor AXI inspection market reached KRW 18.87 billion in cumulative Q3 2026.

AXI (automated X-ray inspection) equipment checks semiconductor packages for internal defects without destroying them. The company says it is widening its customer base for CMOS detectors used in semiconductor inspection equipment.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩29.3B₩1B3.5%
2025Q4₩29.1B-₩2.9B−10.0%
2026Q1₩36.8B₩3.6B9.8%
2026Q2₩36.5B₩2.5B6.9%
2026Q3₩35.9B₩3.5B9.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩147.2B₩25.4B₩22B17.2%9.8%16.2%
2023₩143B₩19.7B₩19.6B13.8%8.2%15.2%
2024₩125.6B₩6.6B₩7.8B5.3%3.2%10.0%
2025₩114.7B-₩4B-₩5.3B−3.4%−2.2%10.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a disclosed annual basis, revenue fell from KRW 147.2 billion in 2022 to KRW 143 billion in 2023 (down 2.8% year over year), KRW 125.6 billion in 2024 (down 12.2%) and KRW 114.7 billion in 2025 (down 8.6%), a three-year consecutive decline; 2022 was the largest year of the 2022 to 2025 span.

Operating profit went from KRW 25.4 billion in 2022 to KRW 19.7 billion in 2023 (down 22.3%) and KRW 6.63 billion in 2024 (down 66.3%), then turned into an operating loss of KRW 3.95 billion in 2025.

The operating margin slid from 17.2% to 13.8% and 5.3%, reaching -3.4% in 2025; profit fell far faster than revenue, so margin pressure was central to the deterioration.

Attributable net income went from KRW 22 billion in 2022 to KRW 19.6 billion in 2023 (down 11.1%) and KRW 7.83 billion in 2024 (down 60.1%), then turned into an attributable net loss of KRW 5.28 billion in 2025.

Net income including non-controlling interests was a loss of KRW 5.32 billion in 2025 and should be read separately from the attributable figure. Operating cash flow fell from KRW 16.6 billion in 2022, KRW 25.8 billion in 2023 and KRW 24.8 billion in 2024 to KRW 9.21 billion in 2025, but stayed positive.

At the end of 2025, the debt-to-equity ratio was 10.0%, with total equity of KRW 237.4 billion, of which KRW 237 billion was attributable to shareholders, and total liabilities of KRW 23.9 billion.

Quarterly revenue went from KRW 29.3 billion in Q3 2025 and KRW 29.1 billion in Q4 2025 (down 0.7% quarter on quarter) to KRW 36.8 billion in Q1 2026 (up 26.1%).

It then declined to KRW 36.5 billion in Q2 2026 (down 0.8%) and KRW 35.9 billion in Q3 2026 (down 1.6%), two straight quarterly declines, although Q3 revenue still rose 22.2% from a year earlier.

Operating profit went from KRW 1.01 billion in Q3 2025 to an operating loss of KRW 2.92 billion in Q4 2025, then recovered to KRW 3.58 billion in Q1 2026, KRW 2.51 billion in Q2 (down 29.9%) and KRW 3.51 billion in Q3 (up 39.9% quarter on quarter and up 246.3% year over year).

The company cited cost improvements, higher yields and operating leverage from higher sales as the Q3 drivers. Attributable net income in Q3 2026 was a loss of KRW 1.42 billion, and press calculations put the quarter's non-operating loss at roughly KRW 5.4 billion.

05

Industry analysis

Digital X-ray detectors are moving beyond dental and medical uses into industrial applications such as semiconductor inspection equipment. The company says TFT detectors suit still imaging and large-area capture, while CMOS detectors suit high-resolution video.

The company has said the expansion of the AI semiconductor market is a new growth driver for its industrial CMOS business. AXI equipment finds internal defects in semiconductor packages, so chip-industry investment flows tend to reach detector demand.

Cumulative AXI-related sales through Q3 2026 exceeding the full-year 2025 level shows how quickly the industrial business has grown. In dental, the company's existing strength in intraoral sensors supported a 38.5% rise in Q3 dental sales. Veterinary imaging rose 21.3% and shares the sales base with dental.

On competition, the company stresses that it is the only domestic maker producing both TFT and CMOS detectors, which points to a strategy of offering both technologies for different applications.

Securities reports published in August 2026 also treated growth in CMOS detectors for semiconductor inspection as a main theme. Where the sector sits in its cycle, however, depends on how long AXI demand lasts.

06

Outlook

In its Q2 2026 preliminary release of August 11, 2026, the company set strengthening its industrial business as the second-half priority, citing new customer wins, wider mass-production conversion and new product supply. In dental and veterinary markets, it said it would expand cooperation with key customers.

In its Q3 2026 preliminary release of November 11, 2026, it kept as priorities new customer development in industrial and medical detectors and a wider customer base for detectors used in semiconductor inspection equipment. It also said cost improvements and higher production yields remain central to profitability.

A portable and mobile X-ray integrated solution launch appears in the company's news listings, pointing to mobile medical imaging as another product line. On governance, a change of chief executive was disclosed on June 1, 2026, and the CEO named in the November 2026 release is Young Kwon Seo.

The outlook in the company's releases is directional and qualitative, without numerical annual revenue or profit targets. The next checkpoints are therefore the full-year results to be confirmed in the 2026 annual report and whether operating profit stays positive in Q4.

07

Valuation

PER
408.3×
PBR
0.5×
ROE
0.1%
EPS
₩18
BPS
₩15,444
Dividend per share
₩300

Based on attributable net income for the last four quarters, the total is only KRW 300 million, so the price-to-earnings multiple sits at a high level relative to the earnings base.

This mainly reflects the attributable net loss in Q3 2026, which came despite operating profit rising 246.3% year over year, because of a non-operating loss. The price-to-book ratio is below 1x, and market capitalization sits below total equity, so the shares trade at a discount to net asset value.

The debt-to-equity ratio of 10.0% at the end of 2025 means leverage distortion in the multiple is limited. Operating profit makes the multiple look low, while attributable net income makes it look high, so the result depends heavily on which earnings base is used.

Since 2025, attributable net income has alternated between losses in Q4 2025 and Q3 2026 and profits in Q1 and Q2 2026, so earnings-based multiples can move sharply from quarter to quarter. Dividends are being paid while operating cash flow remains positive, and dividend capacity is read alongside that cash flow trend.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

AXI inspection sales already exceed the full-year 2025 level

According to the company's preliminary release of November 11, 2026, sales to the semiconductor AXI inspection market reached KRW 18.87 billion in cumulative Q3 2026, above the KRW 13 billion recorded for 2025. Industrial detector sales in Q3 rose 43.3% to KRW 5.11 billion.

Industrial sales had risen 140.9% in Q2 according to the August 11, 2026 preliminary release. The company named widening its customer base for semiconductor inspection detectors as a second-half priority.

Operating profit stays positive with margin recovery

Operating profit moved from an operating loss of KRW 3.95 billion in 2025 to KRW 3.58 billion in Q1 2026, KRW 2.51 billion in Q2 and KRW 3.51 billion in Q3, staying positive throughout. The company's preliminary release put the Q3 operating margin at 9.8%, up 6.3 percentage points from a year earlier. It attributed the improvement to cost reductions, higher yields and operating leverage from higher sales.

A dental sensor base keeps demand steady

Dental sales reached KRW 13.28 billion in Q3 2026, up 38.5% year over year. The company's claim to be the only domestic maker of both TFT and CMOS detectors is cited as a strength linking its dental and industrial technology base.

09

Bear factors

Attributable net income keeps swinging into losses

Attributable net income turned into a KRW 5.28 billion loss in 2025, followed by a KRW 6.71 billion loss in Q4 2025 and a KRW 1.42 billion loss in Q3 2026. The last four quarters together total only KRW 300 million.

Press calculations put the Q3 non-operating loss at about KRW 5.4 billion, so operating profit did not carry through to net income.

Revenue decline and quarterly volatility

Annual revenue declined for three straight years, from KRW 147.2 billion in 2022 to KRW 114.7 billion in 2025. After peaking at KRW 36.8 billion in Q1 2026, quarterly revenue fell for two straight quarters to KRW 36.5 billion and KRW 35.9 billion.

Operating profit dropped 29.9% in Q2 to KRW 2.51 billion before recovering to KRW 3.51 billion in Q3, showing wide swings.

Dependence on AI chip-related demand

Industrial growth centers on AXI inspection demand, so it depends on the pace of semiconductor equipment investment. Q3 2026 industrial detector sales of KRW 5.11 billion are only part of total revenue, which is shared with dental and veterinary segments.

The company keeps citing new customer acquisition as a priority, so reducing reliance on specific demand sources is still a work in progress.

10

Risk factors

Non-operating profit and loss volatility

Q3 2026 operating profit was KRW 3.51 billion, yet the attributable net loss was KRW 1.42 billion. Press calculations put the non-operating loss at about KRW 5.4 billion. Because the nature and size of non-operating items can change each quarter, operating profit alone does not show the direction of net income.

Quarterly profitability tied to cost and yield

The company cited cost improvements and higher production yields as drivers of profitability. Operating margin was 6.9% in Q2 2026 and rose to 9.8% in Q3. Whether the gain holds depends on continued yield improvement and cost reduction, and later quarters will show whether one quarter's improvement becomes a trend.

Exposure to the semiconductor cycle in industrial demand

Industrial sales are tied to AI chip equipment investment, so any change in that spending can flow directly into AXI-related detector demand. If AI chip demand keeps expanding, the industrial business has room to grow.

Either way, the larger the industrial share becomes, the more the company is exposed to the semiconductor cycle.

11

What to watch next

  1. By end of March 2027

    The 2026 annual report will confirm full-year revenue, operating profit and attributable net income. The key points are whether Q4 turns loss-making again, as it did in Q4 2025, and how much of the Q3 non-operating loss carries into full-year net income.

  2. Around March 2027

    The annual general meeting notice was issued on March 9, 2026. The agenda and any dividend decision for the 2027 meeting will show the direction of shareholder returns.

  3. Around mid-May 2027

    The Q1 2027 preliminary release, which came on May 12 in 2026, will show whether quarterly revenue exceeds the KRW 36.8 billion of Q1 2026. It will also show whether AXI-related sales hold up on a quarterly basis.

  4. Around mid-August 2027

    The Q2 2027 preliminary release, which came on August 11 in 2026, is the next checkpoint. It will show whether new customer wins and wider mass-production conversion, the company's stated second-half priorities, are reflected in sales and operating margin.

12

Overall view

Rayence's Q1 to Q3 2026 results show a clear improvement in direction, with operating profit turning positive on the back of industrial CMOS detectors and AXI inspection sales. Dental and veterinary sales also rose by double digits year over year.

However, annual revenue has declined for three straight years since 2022, and 2025 brought an operating loss and an attributable net loss.

In Q3 2026 operating profit was positive, but a non-operating loss produced an attributable net loss, and attributable net income for the last four quarters totals only KRW 300 million. On valuation, a low multiple to net assets and a high multiple to earnings coexist.

Strengths are the dental intraoral sensor franchise, the two-technology detector base and growing AXI demand. Weaknesses are the post-peak revenue decline, non-operating earnings volatility and exposure to the semiconductor cycle in industrial demand.

The next checkpoints are the full-year results to be confirmed in the 2026 annual report and the Q1 2027 preliminary release.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. vatechnetworks.com
  2. rapportian.com
  3. newstap.co.kr
  4. pinpointnews.co.kr
  5. supple.kr
  6. newsway.co.kr
  7. mt.co.kr
  8. m.news.nate.com
  9. vegannews.co.kr
  10. dentalarirang.com
  11. rayence.com
  12. rayence.com
  13. vegannews.co.kr
  14. rayence.com
  15. vatechnetworks.com
  16. m.irgo.co.kr

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis